We analyzed these transcriptional signatures associated with liver fibrosis in the four liver biopsies from Patient 1 (Fig. 4e) and saw reduction in markers of LSEC activation including the fibrogenic LSEC markers CD34, and ACKR1 and the NOTCH3-JAG1 axis that regulates HSCs activation as well as of scar/fibrosis associated mesenchymal cells (SAMec) and macrophages (SAMacs), which were upregulated in biopsies with bridging fibrosis and decreased on dasatinib treatment. This evidence concerns the gene CD34 and Hepatic fibrosis.